Martin Oft

6.9k total citations · 3 hit papers
74 papers, 4.8k citations indexed

About

Martin Oft is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Martin Oft has authored 74 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Oncology, 40 papers in Immunology and 13 papers in Molecular Biology. Recurrent topics in Martin Oft's work include Cancer Immunotherapy and Biomarkers (31 papers), CAR-T cell therapy research (29 papers) and Immunotherapy and Immune Responses (28 papers). Martin Oft is often cited by papers focused on Cancer Immunotherapy and Biomarkers (31 papers), CAR-T cell therapy research (29 papers) and Immunotherapy and Immune Responses (28 papers). Martin Oft collaborates with scholars based in United States, Austria and Germany. Martin Oft's co-authors include Hartmut Beug, Allan Balmain, John L. Langowski, Robert A. Kastelein, Ernst Reichmann, Heinz Schwarz, John B. Mumm, Terrill K. McClanahan, Taiying Chen and Rosemary J. Akhurst and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Martin Oft

71 papers receiving 4.7k citations

Hit Papers

IL-23 promotes tumour incidence and growth 1996 2026 2006 2016 2006 1996 1998 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. IL-23 promotes tumour incidence and growth
    2006 792 citations John L. Langowski, Taiying Chen et al. profile →
  2. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells.
    1996 566 citations Martin Oft, Hartmut Beug et al. profile →
  3. TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis
    1998 525 citations Martin Oft et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Martin Oft United States 26 2.4k 2.3k 1.7k 490 471 74 4.8k
William Damsky United States 32 1.6k 0.7× 1.9k 0.8× 1.4k 0.8× 335 0.7× 536 1.1× 122 4.7k
Ian Kasman United States 20 1.5k 0.6× 2.5k 1.1× 2.1k 1.2× 1.0k 2.1× 433 0.9× 26 5.3k
Noelyn M. Kljavin United States 24 1.3k 0.5× 1.5k 0.7× 1.8k 1.0× 432 0.9× 420 0.9× 29 4.1k
Masatoshi Tagawa Japan 35 1.7k 0.7× 2.3k 1.0× 1.5k 0.9× 564 1.2× 328 0.7× 210 4.6k
Yasuharu Nishimura Japan 44 1.8k 0.7× 2.6k 1.1× 3.0k 1.7× 386 0.8× 259 0.5× 171 6.0k
Eric Eldering Netherlands 46 1.5k 0.6× 2.2k 1.0× 2.5k 1.4× 770 1.6× 1.3k 2.7× 170 6.0k
Angelo A. Cardoso United States 38 1.2k 0.5× 2.0k 0.9× 2.5k 1.5× 349 0.7× 268 0.6× 86 5.3k
Colette Adida France 21 1.8k 0.7× 3.6k 1.6× 1.0k 0.6× 750 1.5× 391 0.8× 24 5.2k
Yoshihiko Hirohashi Japan 40 2.2k 0.9× 2.5k 1.1× 1.9k 1.1× 739 1.5× 138 0.3× 217 4.8k

Countries citing papers authored by Martin Oft

Since Specialization
Citations

This map shows the geographic impact of Martin Oft's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Oft with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Oft more than expected).

Fields of papers citing papers by Martin Oft

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Oft. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Oft. The network helps show where Martin Oft may publish in the future.

Co-authorship network of co-authors of Martin Oft

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Oft. A scholar is included among the top collaborators of Martin Oft based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Oft. Martin Oft is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Aspuria, Paul‐Joseph, Ivan Cheng, Navneet Ratti, et al.. (2023). 228 Engineered human IL-2/IL-2Rß orthogonal pairs selectively enhance anti-GPC3 CAR T cells in vivo to drive complete responses in solid epithelial tumor models. SHILAP Revista de lepidopterología. A260–A260. 1 indexed citations
4.
Oft, Martin, Navneet Ratti, Sandro Vivona, et al.. (2023). Abstract 1801: STK-012, an a/b-selective IL-2 activates tumor antigen specific CD25+ CD8 T cells to reject tumors without acute vascular toxicity. Cancer Research. 83(7_Supplement). 1801–1801. 1 indexed citations
5.
Spigel, David R., Alexander I. Spira, Dmitriy Zamarin, et al.. (2022). Abstract CT244: A phase 1a/1b study of STK-012, an α/β IL-2 receptor selective partial agonist as monotherapy and in combination with pembrolizumab in advanced solid tumors (NCT05098132). Cancer Research. 82(12_Supplement). CT244–CT244. 1 indexed citations
6.
Aspuria, Paul‐Joseph, Sandro Vivona, Navneet Ratti, et al.. (2022). Abstract 2824: Engineered human IL-2/IL-2Rb orthogonal pairs selectively enhance anti-GPC3 CAR T cells to drive complete responses in solid epithelial tumor models. Cancer Research. 82(12_Supplement). 2824–2824.
7.
Aspuria, Paul‐Joseph, Sandro Vivona, Michele Bauer, et al.. (2021). An orthogonal IL-2 and IL-2Rβ system drives persistence and activation of CAR T cells and clearance of bulky lymphoma. Science Translational Medicine. 13(625). eabg7565–eabg7565. 61 indexed citations
8.
Hecht, J. Randolph, Aung Naing, Gerald S. Falchook, et al.. (2017). Overall survival and immunologic responses in metastatic pancreatic adenocarcinoma (PDAC) on PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX). Annals of Oncology. 28. v254–v254. 1 indexed citations
9.
Naing, Aung, Deborah Jean Lee Wong, Jeffrey R. Infante, et al.. (2017). PEGylated human IL-10 (AM0010) in combination with pembrolizumab in anti-PD1 and CTLA-4 refractory melanoma.. Journal of Clinical Oncology. 35(15_suppl). 3084–3084. 3 indexed citations
10.
Chan, Ivan H., Dennis Van Hoof, Brett Jorgensen, et al.. (2016). PEGylated IL-10 Activates Kupffer Cells to Control Hypercholesterolemia. PLoS ONE. 11(6). e0156229–e0156229. 7 indexed citations
11.
Chan, Ivan H., et al.. (2015). The Potentiation of IFN-γ and Induction of Cytotoxic Proteins by Pegylated IL-10 in Human CD8 T Cells. Journal of Interferon & Cytokine Research. 35(12). 948–955. 25 indexed citations
12.
Mumm, John B. & Martin Oft. (2013). Pegylated IL‐10 induces cancer immunity. BioEssays. 35(7). 623–631. 44 indexed citations
13.
Emmerich, Jan, John B. Mumm, Ivan H. Chan, et al.. (2012). IL-10 Directly Activates and Expands Tumor-Resident CD8+ T Cells without De Novo Infiltration from Secondary Lymphoid Organs. Cancer Research. 72(14). 3570–3581. 228 indexed citations
14.
Parry, David, Timothy J. Guzi, Fergus Shanahan, et al.. (2010). Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor. Molecular Cancer Therapeutics. 9(8). 2344–2353. 434 indexed citations
15.
Wang, Yaolin, Xiaoying Wang, Philip Lipari, et al.. (2008). SCH 727965, a novel cyclin-dependent kinase inhibitor, has potent anti-tumor acitivity in a wide-spectrum of human tumor xenograft models. Cancer Research. 68. 1594–1594. 1 indexed citations
16.
Parry, David, Timothy J. Guzi, Wolfgang Seghezzi, et al.. (2007). In vitro and in vivo characterization of SCH727965 a novel potent cyclin dependent kinase inhibitor. Cancer Research. 67. 4371–4371. 3 indexed citations
17.
Langowski, John L., Robert A. Kastelein, & Martin Oft. (2007). Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends in Immunology. 28(5). 207–212. 107 indexed citations
18.
Fialka, Irene, Martin Oft, Ernst Reichmann, Lukas A. Huber, & Hartmut Beug. (1998). Three-dimensional organotypic growth of epithelial cells in reconstituted extracellular matrix.. IRIS. 2 indexed citations
19.
Bevec, Dorian, Herbert Jaksche, Martin Oft, et al.. (1996). Inhibition of HIV-1 Replication in Lymphocytes by Mutants of the Rev Cofactor eIF-5A. Science. 271(5257). 1858–1860. 180 indexed citations
20.
Oft, Martin, Stephan Böhm, Thomas Iftner, & Sharon P. Wilczynski. (1993). Expression of the different viral mRNAs of human papilloma virus 6 in a squamous‐cell carcinoma of the bladder and the cervix. International Journal of Cancer. 53(6). 924–931. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by William Damsky Breakdown of academic impact, for papers by Ian Kasman Breakdown of academic impact, for papers by Noelyn M. Kljavin Breakdown of academic impact, for papers by Masatoshi Tagawa Breakdown of academic impact, for papers by Yasuharu Nishimura Breakdown of academic impact, for papers by Eric Eldering Breakdown of academic impact, for papers by Angelo A. Cardoso Breakdown of academic impact, for papers by Colette Adida Breakdown of academic impact, for papers by Yoshihiko Hirohashi
Rankless by CCL
2026